The penetration of novel intravenous cephalosporins into the lung

Area of Science:

• Pharmacokinetics and Drug Metabolism
• Infectious Diseases
• Respiratory Medicine

Background:

• Relating antimicrobial concentrations at the infection site to the Minimum Inhibitory Concentration (MIC) can indicate clinical efficacy, particularly for less susceptible pathogens.
• Accurate measurement of drug concentrations at infection sites is challenging due to inherent measurement errors, leading to imprecise values.

Purpose of the Study:

• To investigate the relationship between antimicrobial concentrations at infection sites and clinical efficacy.
• To quantify cephalosporin concentrations in various lung compartments (bronchial biopsy, lung tissue, epithelial lining fluid) relative to serum concentrations.

Main Methods:

• Analysis of simultaneous serum and lung tissue/fluid samples to determine drug concentrations.
• Comparison of drug concentrations across different lung compartments and correlation with known drug properties.

Main Results:

• Cephalosporin concentrations in bronchial biopsies reached 35-55% of serum concentrations, in whole lung tissue 15-50%, and in epithelial lining fluid (ELF) 15-35%.
• Observed site-to-serum concentration ratios align with cephalosporin permeability characteristics and barriers to drug penetration.
• Evidence suggests inflammation may increase drug penetration into infection sites.

Conclusions:

• Lung concentrations of cephalosporins show a measurable relationship with serum levels, consistent with drug permeability.
• While trends are emerging, further research is required to definitively link lung drug concentrations to clinical outcomes.
• Understanding drug penetration into lung tissues is crucial for optimizing antimicrobial therapy in respiratory infections.